JPH4

Across TCGA pan-cancer cohorts, JPH4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JPH4 data layer compared with 27 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher JPH4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JPH4 expression acts as an unfavorable survival marker.

KIRP, ESCA, and PRAD are the cancer types where JPH4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.148	0.904	<.001	30	view →
ESCA	OS	Median	II,III,IV	0.164	0.687	.002	15	view →
PRAD	OS	Median	All	0.265	0.884	<.001	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JPH4–KIRP (OS)

Open the KIRP breakdown →